Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Aarhus
With
Aarhus University Hospital
AbbVie
Age
30–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic hepatitis C genotype 1 or 4 patients initiating the new AbbVie treatment (paritaprevir, ritonavir, ombitasvir og dasabuvir sammen med ribavirin)
Child-Pugh A liver cirrhosis
You may not be if
Severe liver dysfunction - Child-Pugh klasse B-C
Life expectancy less than 6 months
planned liver transplantation or TIPS procedure within 6 months
non-compliance to treatment or study procedures
allergy to the DAA drugs used (paritaprevir, ritonavir, ombitasvir, dasabuvir, and ribavirin)
pregnancy or expected pregnancy during the study (anti-conception has to be used)
breast feeding
portal vein thrombosis
liver cancer or other malignancies
alcohol consumption
Clareo Health | Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C
